Lux Health Technologies Ltd 10065887 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is research and experimental development on natural sciences and engineering Digita Accounts Production Advanced 6.30.9574.0 true true 10065887 2023-01-01 2023-12-31 10065887 2023-12-31 10065887 bus:OrdinaryShareClass1 2023-12-31 10065887 core:RetainedEarningsAccumulatedLosses 2023-12-31 10065887 core:ShareCapital 2023-12-31 10065887 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 10065887 bus:SmallEntities 2023-01-01 2023-12-31 10065887 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 10065887 bus:FullAccounts 2023-01-01 2023-12-31 10065887 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 10065887 bus:RegisteredOffice 2023-01-01 2023-12-31 10065887 bus:Director2 2023-01-01 2023-12-31 10065887 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 10065887 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 10065887 1 2023-01-01 2023-12-31 10065887 countries:EnglandWales 2023-01-01 2023-12-31 10065887 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2022-12-31 10065887 2022-01-01 2022-12-31 10065887 2022-12-31 10065887 bus:OrdinaryShareClass1 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10065887

Lux Health Technologies Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2023

Pages for filing with Registrar

 

Lux Health Technologies Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 6

 

Lux Health Technologies Ltd

Company Information

Director

T H Povlsen

Registered office

16 Queen Anne's Gate
London
SW1H 9AA

Registered number

10065887

Accountant

Corrigan Accountants Limited
1st Floor
25 King Street
Bristol
BS1 4PB

 

Lux Health Technologies Ltd

(Registration number: 10065887)
Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Current assets

 

Cash at bank and in hand

 

-

393,016

Capital and reserves

 

Called up share capital

10

10

Profit and loss account

(10)

393,006

Total equity

 

-

393,016

 

Lux Health Technologies Ltd

(Registration number: 10065887)
Balance Sheet as at 31 December 2023 (continued)

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised for issue by the director on 31 January 2024
 

.........................................

T H Povlsen
Director

 

Lux Health Technologies Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

Statutory information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
16 Queen Anne's Gate
London
SW1H 9AA

2

Accounting policies

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in pounds sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Lux Health Technologies Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

2

Accounting policies (continued)

Development costs

Research and development expenditure is written off as incurred, except that development expenditure incurred on an individual project is capitalised as an intangible asset when the company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the asset and the ability to measure reliably the expenditure during development.

Following initial recognition of the development expenditure as an asset, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade creditors

Trade creditors are recognised at the transaction price.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2022 - 1).

 

Lux Health Technologies Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

4

Intangible fixed assets

Development costs
£

Cost

At 1 January 2023

1,389,665

At 31 December 2023

1,389,665

Amortisation

At 1 January 2023

1,389,665

At 31 December 2023

1,389,665

Carrying amount

At 31 December 2023

-

5

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary shares of £1 each

10

10

10

10

         

6

Parent and ultimate parent undertaking

The company's immediate parent is Nine United Properties UK Ltd, incorporated in England and Wales.